Canada Life’s BioXcel Therapeutics BTAI Stock Holding History

Canada Life’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-46	Closed	-$2K	–	2177
2023 Q3	$2K	Hold	46	–	–	﹤0.01%	2232
2023 Q2	$5K	Hold	46	–	–	﹤0.01%	2253
2023 Q1	$14K	Hold	46	–	–	﹤0.01%	2269
2022 Q4	$16K	Hold	46	–	–	﹤0.01%	2281
2022 Q3	$9K	Hold	46	–	–	﹤0.01%	2348
2022 Q2	$10K	Hold	46	–	–	﹤0.01%	2357
2022 Q1	$16K	Hold	46	–	–	﹤0.01%	2386
2021 Q4	$15K	Hold	46	–	–	﹤0.01%	2417
2021 Q3	$22K	Hold	46	–	–	﹤0.01%	2409
2021 Q2	$21K	Hold	46	–	–	﹤0.01%	2473
2021 Q1	$31K	Hold	46	–	–	﹤0.01%	2434
2020 Q4	$34K	Hold	46	–	–	﹤0.01%	2406
2020 Q3	$32K	Hold	46	–	–	﹤0.01%	2300
2020 Q2	$39K	Buy	+46	New	+$30K	﹤0.01%	2301

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Canada Life's BTAI Position: Q4 2023 in Review

Canada Life sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 46 shares — an estimated $2K sold.

Canada Life first reported a position in BTAI in Q2 2020 and held it in 14 quarters. The position peaked at $39K in Q2 2020. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

Canada Life reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
Canada Life sold 46 BioXcel Therapeutics shares in Q4 2023, an estimated $2K.
Canada Life first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 14 quarters.
Canada Life's BioXcel Therapeutics position peaked at $39K in Q2 2020.
73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Canada Life's 13F filing for Q4 2023, filed 13 Feb 2024.